Rare cancers encompass a diverse group of malignancies that individually affect a limited number of patients. These diseases, while individually rare, collectively impact a significant portion of the population.Â
Current treatments often face challenges due to limited research and understanding, resulting in a lack of standardized therapeutic approaches. However, recent advancements in oncology have sparked a renewed focus on these less common malignancies. Precision medicine, immunotherapies, and targeted therapies are emerging as promising avenues, tailoring treatments to the specific genetic and molecular characteristics of each rare cancer.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Our supporting partners do not constitute an endorsement of the content on this page.
In this Future Leaders interview, Dr Di Carlo reflects on the mentors who shaped her career, the lessons of resilience and authenticity she carries forward, and the importance of aligning personal values with patient-centered care and lifelong learning in oncology.
Three experts discuss the latest advances in PNH pathophysiology, diagnosis and therapeutics.
Rare gastrointestinal (GI) cancers present unique challenges in diagnosis, treatment and research. Dr. Benjamin Weinberg discusses three of the rarest GI cancers: small bowel, appendix and anal cancer.
Three expert haematologists discuss current and emerging treatments for ITP as well as the disease burden.
Leading experts discuss the impact of ITP on patients and review current and emerging treatment strategies.
Three experts share insights into the treatment and care of patients with NF1 from childhood to adulthood.
Experts provide insights on tailoring treatment in patients with EGFR-mutant and wildtype NSCLC.
Three experts discuss data presented at EHA and ISTH 2024 on the impact and management of ITP.
Two haematologic oncologists discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.